The pursuit of continuous innovation

eCMSadmin — Wed, 08 Sep 2021 00:00:00 +0000

Dhaval Patel, Patient Value Early Solutions

eCMSadmin Wed 08/09/2021 - 02:00

From unlocking the secrets of chemicals, cultivating the promises of pharmaceuticals and expanding into biologics, peptides and gene therapy, our researchers at ��ֳ� are on a mission to continuously innovate. To do that, we are harnessing today’s new frontiers in science and technology and strengthening our capabilities to discover and develop new medicines. So, it should come as no surprise that we are utilising some unique disruptive technology to help strengthen our gene therapy activities.

We recently signed an agreement with CEVEC Pharmaceuticals to evaluate and gain access to their ELEVECTA® technology. ELEVECTA® technology may enable ��ֳ� to develop a scalable, robust and efficient manufacturing of gene therapy vectors. Up until now, manufacturing of adeno-associated viral vectors (AAVs) has been an expensive and challenging process usually requiring multiple batches of transient transfection of cells lines and large quantities of cGMP-quality plasmids. The CEVEC technology overcomes these limitations based on producer cell-lines which have all the necessary elements for AAV production integrated in one cell. This enables superior, efficient, high-performance, industry scale AAV production from one cell line with consistent quality.

At ��ֳ� we have world class discovery, research, development and manufacturing facilities and to maintain this position we will continuously monitor new and disruptive technologies in the pursuit of innovation.

You can read more about our R&D global footprint and explore the gene therapy opportunities at ��ֳ� by visiting our recruitment page here.

innovation

869 Likes

With more than 90 years of innovation behind us, we are looking to the future

eCMSadmin — Wed, 07 Jul 2021 00:00:00 +0000

With more than 90 years of innovation behind us, we are looking to the future

Luc Uylenbroeck, Patient Value Early Solutions

eCMSadmin Wed 07/07/2021 - 02:00

��ֳ�’s ambition for patients relies on our ability to innovate and deliver highly differentiated medicines with unique outcomes. Today, following the recent acquisition of Handl Therapeutics BV, we are marking their full integration into the ��ֳ� family. This is great news as it advances our ability to develop novel treatments using state of the art gene therapy technology.

��ֳ� has a vision to move from symptomatic treatments to disease modification and eventually towards a cure. Adeno-associated virus (AAV) mediated gene therapy offers to deliver that potential and drive a fundamental change in how diseases are treated with the ability to remove or add disease-related proteins with a single treatment. A vast array of severe diseases are amenable to gene therapy and ��ֳ� is embracing this modality to expand its capabilities and ultimately transform the lives of patients with severe diseases.

Handl Therapeutics BV is a Leuven-based, Belgium born, transformative gene therapy company with a vision to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases. Operating in a highly collaborative manner, the company built a strong international network to access global capabilities and expertise. To this end, it combines state of the art technology platforms and scientific advances licenced from KU Leuven (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navarra, Spain), University of Chile (Chile) and King’s College London (UK) to address unmet medical needs.

Over the past 90 years, we have been on an incredible journey to become the company you see today. We’ve evolved and adapted but always looked to innovate and deliver highly differentiated medicines.

innovation

Handl Therapeutics Gene Therapy AAV

Comment:

Posted by Naoto Matsuda, 9 July 2021

Looking forward to the potential indications we will pursue with the technology.

Comment:

Posted by Dr. Sumantoke Bagchi, 9 July 2021

90 years of research led solutions for patients suffering from allergy, neurologic disorder to another century of futuristic solutions. Keep it going ��ֳ�

834 Likes

AAV

The pursuit of continuous innovation

Leave a Comment

With more than 90 years of innovation behind us, we are looking to the future

Leave a Comment